216 related articles for article (PubMed ID: 24244025)
1. Differences in the phenotype, cytokine gene expression profiles, and in vivo alloreactivity of T cells mobilized with plerixafor compared with G-CSF.
Lundqvist A; Smith AL; Takahashi Y; Wong S; Bahceci E; Cook L; Ramos C; Tawab A; McCoy JP; Read EJ; Khuu HM; Bolan CD; Joo J; Geller N; Leitman SF; Calandra G; Dunbar C; Kurlander R; Childs RW
J Immunol; 2013 Dec; 191(12):6241-9. PubMed ID: 24244025
[TBL] [Abstract][Full Text] [Related]
2. Impact of donor hematopoietic cells mobilized with G-CSF and plerixafor on murine acute graft-versus-host-disease.
Arbez J; Saas P; Lamarthée B; Malard F; Couturier M; Mohty M; Gaugler B
Cytotherapy; 2015 Jul; 17(7):948-55. PubMed ID: 25813681
[TBL] [Abstract][Full Text] [Related]
3. Accelerated lymphocyte reconstitution and long-term recovery after transplantation of lentiviral-transduced rhesus CD34+ cells mobilized by G-CSF and plerixafor.
Uchida N; Bonifacino A; Krouse AE; Metzger ME; Csako G; Lee-Stroka A; Fasano RM; Leitman SF; Mattapallil JJ; Hsieh MM; Tisdale JF; Donahue RE
Exp Hematol; 2011 Jul; 39(7):795-805. PubMed ID: 21549175
[TBL] [Abstract][Full Text] [Related]
4. Superior long-term repopulating capacity of G-CSF+plerixafor-mobilized blood: implications for stem cell gene therapy by studies in the Hbb(th-3) mouse model.
Psatha N; Sgouramali E; Gkountis A; Siametis A; Baliakas P; Constantinou V; Athanasiou E; Arsenakis M; Anagnostopoulos A; Papayannopoulou T; Stamatoyannopoulos G; Yannaki E
Hum Gene Ther Methods; 2014 Dec; 25(6):317-27. PubMed ID: 25333506
[TBL] [Abstract][Full Text] [Related]
5. The CXCR4 and adhesion molecule expression of CD34+ hematopoietic cells mobilized by "on-demand" addition of plerixafor to granulocyte-colony-stimulating factor.
Girbl T; Lunzer V; Greil R; Namberger K; Hartmann TN
Transfusion; 2014 Sep; 54(9):2325-35. PubMed ID: 24673458
[TBL] [Abstract][Full Text] [Related]
6. Plerixafor (AMD3100) and granulocyte colony-stimulating factor (G-CSF) mobilize different CD34+ cell populations based on global gene and microRNA expression signatures.
Donahue RE; Jin P; Bonifacino AC; Metzger ME; Ren J; Wang E; Stroncek DF
Blood; 2009 Sep; 114(12):2530-41. PubMed ID: 19602709
[TBL] [Abstract][Full Text] [Related]
7. Differences in Cellular Composition of Peripheral Blood Stem Cell Grafts from Healthy Stem Cell Donors Mobilized with Either Granulocyte Colony-Stimulating Factor (G-CSF) Alone or G-CSF and Plerixafor.
Teipel R; Oelschlägel U; Wetzko K; Schmiedgen M; Kramer M; Rücker-Braun E; Hölig K; von Bonin M; Heidrich K; Fuchs A; Ordemann R; Kroschinsky F; Bornhäuser M; Hütter G; Schmidt H; Ehninger G; Schetelig J; Heidenreich F
Biol Blood Marrow Transplant; 2018 Nov; 24(11):2171-2177. PubMed ID: 29935214
[TBL] [Abstract][Full Text] [Related]
8. Donor pretreatment with progenipoietin-1 is superior to granulocyte colony-stimulating factor in preventing graft-versus-host disease after allogeneic stem cell transplantation.
MacDonald KP; Rowe V; Filippich C; Thomas R; Clouston AD; Welply JK; Hart DN; Ferrara JL; Hill GR
Blood; 2003 Mar; 101(5):2033-42. PubMed ID: 12393418
[TBL] [Abstract][Full Text] [Related]
9. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the content and subpopulations of CD3 and CD34 positive cells in bone marrow harvests and G-CSF-mobilized peripheral blood leukapheresis products from healthy adult donors.
Hassan HT; Stockschläder M; Schleimer B; Krüger W; Zander AR
Transpl Immunol; 1996 Dec; 4(4):319-23. PubMed ID: 8972563
[TBL] [Abstract][Full Text] [Related]
11. Hematopoietic stem cell mobilization for gene therapy: superior mobilization by the combination of granulocyte-colony stimulating factor plus plerixafor in patients with β-thalassemia major.
Yannaki E; Karponi G; Zervou F; Constantinou V; Bouinta A; Tachynopoulou V; Kotta K; Jonlin E; Papayannopoulou T; Anagnostopoulos A; Stamatoyannopoulos G
Hum Gene Ther; 2013 Oct; 24(10):852-60. PubMed ID: 24001178
[TBL] [Abstract][Full Text] [Related]
12. Impact of Single-Dose Plerixafor as an Adjunct to Granulocyte Colony-Stimulating Factor-Based Peripheral Blood Stem Cell Mobilization on the Graft Composition and Outcome for T Cell-Replete Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide: A Comparative Study.
Jaiswal SR; Bhakuni P; Joy A; Murli N; Bharadwaj P; Zaman S; Nedunchezian M; Chakrabarti S
Biol Blood Marrow Transplant; 2018 Mar; 24(3):542-548. PubMed ID: 29191663
[TBL] [Abstract][Full Text] [Related]
13. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
Steinberg M; Silva M
Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493
[TBL] [Abstract][Full Text] [Related]
14. Blood graft lymphocyte subsets after plerixafor injection in non-Hodgkin's lymphoma patients mobilizing poorly with chemotherapy plus granulocyte-colony-stimulating factor.
Varmavuo V; Mäntymaa P; Kuittinen T; Nousiainen T; Jantunen E
Transfusion; 2012 Aug; 52(8):1785-91. PubMed ID: 22304442
[TBL] [Abstract][Full Text] [Related]
15. Granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation maintains graft-versus-leukemia effects through a perforin-dependent pathway while preventing graft-versus-host disease.
Pan L; Teshima T; Hill GR; Bungard D; Brinson YS; Reddy VS; Cooke KR; Ferrara JL
Blood; 1999 Jun; 93(12):4071-8. PubMed ID: 10361103
[TBL] [Abstract][Full Text] [Related]
16. Modification of T cell responses by stem cell mobilization requires direct signaling of the T cell by G-CSF and IL-10.
MacDonald KP; Le Texier L; Zhang P; Morris H; Kuns RD; Lineburg KE; Leveque L; Don AL; Markey KA; Vuckovic S; Bagger FO; Boyle GM; Blazar BR; Hill GR
J Immunol; 2014 Apr; 192(7):3180-9. PubMed ID: 24585878
[TBL] [Abstract][Full Text] [Related]
17. Characterization of peripheral blood stem cell grafts mobilized by granulocyte colony-stimulating factor and plerixafor compared with granulocyte colony-stimulating factor alone.
Gaugler B; Arbez J; Legouill S; Tiberghien P; Moreau P; Derenne S; Saas P; Mohty M
Cytotherapy; 2013 Jul; 15(7):861-8. PubMed ID: 23731764
[TBL] [Abstract][Full Text] [Related]
18. Machine learning-based scoring models to predict hematopoietic stem cell mobilization in allogeneic donors.
Xiang J; Shi M; Fiala MA; Gao F; Rettig MP; Uy GL; Schroeder MA; Weilbaecher KN; Stockerl-Goldstein KE; Mollah S; DiPersio JF
Blood Adv; 2022 Apr; 6(7):1991-2000. PubMed ID: 34555850
[TBL] [Abstract][Full Text] [Related]
19. Enhanced antileukemic activity of allogeneic peripheral blood progenitor cell transplants following donor treatment with the combination of granulocyte colony-stimulating factor (G-CSF) and stem cell factor (SCF) in a murine transplantation model.
Hartung G; Zeis M; Glass B; Dreger P; Steinmann J; Schmitz N; Uharek L
Bone Marrow Transplant; 2003 Jul; 32(1):49-56. PubMed ID: 12815478
[TBL] [Abstract][Full Text] [Related]
20. Plerixafor on demand in ten healthy family donors as a rescue strategy to achieve an adequate graft for stem cell transplantation.
Gattillo S; Marktel S; Rizzo L; Malato S; Malabarba L; Coppola M; Assanelli A; Milani R; De Freitas T; Corti C; Bellio L; Ciceri F
Transfusion; 2015 Aug; 55(8):1993-2000. PubMed ID: 25721167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]